Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of Grazax Immunotherapy in Grass Pollen Allergy
NCT01854736Phase 4Completed
- Sponsor
- ALK-Abelló
- Start
- Apr 2013
- Primary completion
- Dec 2015
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in allergic rhinitis (AR) comparing Grazax Group with Placebo Group (2 arms). Primary endpoint: Cellular populations (neutrophils, eosinophils, basophils, monocytes, DCs and lymphocytes populations) at 2 years. Started Apr 2013; status: completed.
02
Drugs
grass-pollen extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT01854736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01854736.